Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesJan 24, 2012Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
8-KReport of unscheduled material events or corporate eventJan 6, 2012Open Report of unscheduled material events or corporate event in HTML.Open Report of unscheduled material events or corporate event in DOC file.Open Report of unscheduled material events or corporate event in PDF file.Open Report of unscheduled material events or corporate event in XLS file.
4Statement of changes in beneficial ownership of securitiesJan 5, 2012Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
4Statement of changes in beneficial ownership of securitiesJan 5, 2012Open Statement of changes in beneficial ownership of securities in HTML.Open Statement of changes in beneficial ownership of securities in DOC file.Open Statement of changes in beneficial ownership of securities in PDF file.Open Statement of changes in beneficial ownership of securities in XLS file.
1-25      26-50      51-75      76-100      101-125      126-150      151-154

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information